Evidence map›Paper›PMID 41712131›Full record

ArticleMedical oncology (Northwood, London, England)2026

Engineered mesenchymal stem cells expressing CXCR4 and LIGHT enhance Anti-Tumor activity in a subcutaneous gastric cancer xenograft model.

Umer Anayyat, Jianbin Ye, Xumin Wu, Zhiyu Liu, Cui Liao, Xiaomei Wang, Muyun Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Umer AnayyatNational Engineering Research Center of Foundational Technologies for CGT Industry, Shenzhen, Guaongdong, P. R. China.
Jianbin YeNational Engineering Research Center of Foundational Technologies for CGT Industry, Shenzhen, Guaongdong, P. R. China.
Xumin WuNational Engineering Research Center of Foundational Technologies for CGT Industry, Shenzhen, Guaongdong, P. R. China.
Zhiyu LiuNational Engineering Research Center of Foundational Technologies for CGT Industry, Shenzhen, Guaongdong, P. R. China.
Cui LiaoNational Engineering Research Center of Foundational Technologies for CGT Industry, Shenzhen, Guaongdong, P. R. China.
Xiaomei WangSchool of Biomedical Engineering Sciences, Shenzhen University, Shenzhen, 518061, Guangdong, China.
Muyun LiuNational Engineering Research Center of Foundational Technologies for CGT Industry, Shenzhen, Guaongdong, P. R. China. muyun@ncgt.org.cn.

Funding

Innovation Capacity Building Project, National Engineering Research Center of Foundational Technologies for CGT Industry NDRC-High-Technology[2023]No. 447 to Muyun Liu
6 · The paper itself

Abstract

Gastric cancer remains a leading cause of cancer-related mortality, with limited treatment options and a poor prognosis. Mesenchymal stem cells (MSCs) possess inherent tumor-homing ability but exhibit modest efficacy against solid tumors. Enhancing both tumor targeting and immune activation through genetic modification may improve the therapeutic potential of these approaches. To evaluate the anti-cancer efficacy of human umbilical cord–derived MSCs (HUC-MSCs) genetically modified to co-express C-X-C chemokine receptor type 4 (CXCR4) and TNFSF14 (LIGHT) against gastric cancer in vitro and in vivo. HUC-MSCs were transduced via lentiviral vectors to generate dual-gene–engineered Tg-HUC-MSCs. In vitro, their effects on HGC-27 gastric cancer cells were assessed using the scratch wound migration assay and Annexin V/PI apoptosis analysis. In vivo, BALB/c nude mice bearing subcutaneous HGC-27 xenografts were treated with Tg-HUC-MSCs, unmodified HUC-MSCs, or a control. Tumor growth was monitored by caliper measurements. Excised tumors were analyzed histologically with hematoxylin–eosin staining and by Ki-67 immunohistochemistry. Tg-HUC-MSCs significantly inhibited HGC-27 cell migration and induced higher apoptosis rates than unmodified HUC-MSCs in vitro (p < 0.001). In vivo, Tg-HUC-MSCs markedly reduced tumor volume, increased necrotic areas, and decreased Ki-67 proliferation indices compared to controls (p < 0.001). Elevated CXCR4 and LIGHT expression correlated with improved tumor targeting and enhanced immune-mediated tumor cell killing. Dual-gene–engineered HUC-MSCs (CXCR4 + TNFSF14) demonstrated superior tumor-homing and anti-cancer activity against gastric cancer cells in vitro and in vivo, representing a promising cell-based therapeutic strategy for solid tumors.

Indexed as

Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationReceptors, CXCR4Stomach NeoplasmsTumor Necrosis Factor Ligand Superfamily Member 14AnimalsApoptosisCell Line, TumorCell MovementCell ProliferationFemaleHumansMiceMice, Inbred BALB CMice, NudeXenograft Model Antitumor AssaysCXCR4 protein, humanReceptors, CXCR4TNFSF14 protein, humanTumor Necrosis Factor Ligand Superfamily Member 14CXCR4Gastric cancerTargeted tumor therapyTNFSF14 (LIGHT)Umbilical cord blood mesenchymal stem cells (UCB-MSCs)

Identifiers

PMID41712131
PMCPMC12920293

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.